Advertisement
YOU ARE HERE: LAT HomeCollectionsUrinary Incontinence
IN THE NEWS

Urinary Incontinence

BUSINESS
September 13, 1995 | CHRIS WOODYARD
A day after announcing another major acquisition, Urohealth Systems Inc. said Tuesday that it has agreed to purchase a New Jersey-based maker of surgical and gynecological instruments in a deal valued at $12 million. Urohealth, based in Costa Mesa, said it will issue 3 million new shares of common stock to acquire Advanced Surgical Inc. of Princeton, its fifth acquisition in a year. Urohealth had announced Monday that it will acquire Osbon Medical Systems Ltd. of Augusta, Ga.
Advertisement
SCIENCE
July 29, 2006 | Denise Gellene, Times Staff Writer
Research out of UCLA this week sounds like a dream come true: Scientists say they have found a way to turn fat cells into muscle. As reported in the Proceedings of the National Academy of Sciences, researchers took stem cells from fat donated by liposuction patients and treated the cells with chemicals to produce functioning muscle cells. When stimulated with drugs, scientists said, the tiny muscle cells flexed and stretched -- perfectly toned. Dr. Albert D.
CALIFORNIA | LOCAL
January 12, 1995
Your article "The Disease Men Try to Ignore" (Jan. 2) contains some unfortunate errors of fact concerning treatment of prostate cancer with radiation therapy as an alternative to radical prostatectomy. The first is the assertion that "most studies have found a five-year survival rate of about 20%." Any comparison of survival rates between the two treatment options must be based on patients with similar stages of disease, and when this is done, there is no demonstrable difference in survival between patients treated with surgery or radiation therapy.
NEWS
February 22, 2002
Endocare Inc., an Irvine maker of surgical devices, said Thursday it will acquire closely held Timm Medical Technologies Inc. for $34.8 million in cash and stock to expand its urology business and add to its national sales division. Endocare will pay $11 million in cash and 1.62 million shares of Endocare common stock, valued at $23.8 million at Thursday's close, said Len Hall, a spokesman for Endocare. The stock closed at $14.69, up 72 cents, on Nasdaq.
BUSINESS
March 29, 2002 | From Bloomberg News
Watson Pharmaceuticals Inc. said U.S. regulators rejected a skin patch for urinary incontinence that analysts called the generic-drug maker's most important new product. Watson shares fell 12%. The Food and Drug Administration asked for more clinical data on the patch, called Oxytrol. The company has research not yet seen by the FDA, comparing Oxytrol to Pharmacia Corp.'s Detrol, that may resolve the agency's concerns, Watson Chief Executive Allen Chao said during a conference call.
BUSINESS
February 28, 2003 | Karen Robinson-Jacobs, Times Staff Writer
Shares of Watson Pharmaceuticals Inc. gained nearly 10% on Thursday after the Corona-based drug maker won regulatory approval to market a skin patch to treat overactive bladders. Watson, one of the nation's largest makers of generic drugs, said sales of the patch could bring in $40 million to $50 million this year and that the figure could grow to $200 million by 2008. "This was a long-awaited approval," said Ian Sanderson, a Boston-based pharmaceuticals analyst with SC Cowen.
HEALTH
April 22, 2002 | RIDGELY OCHS, NEWSDAY
An international panel has concluded that, based on current evidence, there are questions about using hormone replacement therapy for more than relieving menopausal symptoms such as hot flashes.
HEALTH
July 9, 2001
The type and cause of urinary incontinence can vary. A urologist will discuss prevention and treatment in a seminar Friday at Borders Bookstore, The Block at Orange, 10 a.m. Free. (877) UCI-DOCS. EDUCATION Wednesday "Fight Breast Cancer With Your Bare Hands" will focus on self-examination and prevention. Citrus Valley Medical Center, Queen of the Valley Campus, 1115 S. Sunset Ave., West Covina. Free. Reservations. (626) 814-2479.
NEWS
May 18, 2011 | By Thomas H. Maugh II, Los Angeles Times/For the Booster Shots blog
High doses of the Alzheimer's drug Aricept should be banned because they are no more effective than low doses and have a sharply increased risk of adverse effects, the advocacy group Public Citizen and a Johns Hopkins University geriatrician said Wednesday in a petition to the Food and Drug Administration. Aricept, known generically as donepezil, is one of the very few drugs available for treating Alzheimer's disease, but it provides only a very modest slowing in the cognitive and functional deficits associated with the disease.
Los Angeles Times Articles
|